What changed
What changedIn the third quarter of 2026, Zoetis revenue fell 1.3% to $2,391 million, and net income declined 18% compared to the same period last year. Financial results reflect operational changes and currency fluctuations.

What changedZoetis reported $2.4 billion in revenue and $591 million in net income for the third quarter of 2026. Following these results, the company narrowed its full-year revenue guidance and raised expectations for adjusted net income.

Dividends & buybacksZoetis Inc. declared a dividend of $0.53 per share for the fourth quarter of 2026, payable on December 1, 2026 to shareholders of record on October 30, 2026

Company history
October 2026
Zoetis Inc.: 10 recorded developments from 4 official sources in 2026-10.
- 2026-10-08: Zoetis Inc. has declared a dividend of $0.53 per share for the fourth quarter of 2026. Source
- 2026-10-08: The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the Company’s common stock as of the close of business on Friday, October 30, 2026. Source
- 2026-10-08: Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Source
- 2026-10-08: On October 8, 2026, the Company declared a dividend of $0.53 per share for the fourth quarter of 2026. Source
- 2026-10-08: The dividend will be paid on December 1, 2026, to all holders of record of the Company's common stock as of the close of business on October 30, 2026. Source
- 2026-10-13: The form of indemnification agreement that Zoetis Inc. will enter into with Ms. Knobloch was previously filed by the Company as Exhibit 10.19 to Amendment No. 4 to the Company’s Registration Statement on Form S-1 (File No. 333-183254), as originally filed with the SEC on August 13, 2012, Source
- 2026-10-13: On October 13, 2026, Zoetis Inc. announced the appointment of Iris Knobloch to its Board of Directors, effective as of December 1, 2026. Source
- 2026-10-13: Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. Source
- 2026-10-13: On October 13, 2026, Zoetis Inc. issued a press release announcing the appointment of Ms. Iris Knobloch to the Board. Source
- 2026-10-13: Ms. Knobloch was not appointed to the Board pursuant to any arrangements or understandings with any third party, and since the beginning of the last fiscal year, there have been no related party transactions between Zoetis Inc. and Ms. Knobloch that would be reportable under Item 404(a) Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
The company remains on track for expected 2026 product approvals.
Said November 5, 2026 · Period named: 2026 · Source · Our article
Not yet checked against later reports.
Select product approvals previously anticipated in 2027 are now expected in the fourth quarter of 2026.
Said November 5, 2026 · Period named: Q4 2026 · Source · Our article
Not yet checked against later reports.
Convenia RTU for Dogs is expected to be available to veterinarians.
Said November 5, 2026 · Period named: first quarter of 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 13, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
| August 6, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 38,528,306 | $2,690,431,629 | -2.3% | Q3 2026 |
| State Street | 19,705,376 | $1,376,026,406 | +0.2% | Q3 2026 |
| Geode Capital Management | 13,272,635 | $923,707,381 | -0.1% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 4,689,847 | $337,012,405 | — | Q2 2026 |
| Citadel Advisors | 1,939,150 | $135,410,844 | -39.2% | Q3 2026 |
| Renaissance Technologies | 1,660,500 | $115,952,715 | +18.3% | Q3 2026 |
| Capital Research Global Investors | 980,811 | $70,481,078 | -30.4% | Q2 2026 |
| Fidelity (FMR) | 925,614 | $64,635,660 | +143.2% | Q3 2026 |
| D. E. Shaw & Co. | 688,352 | $48,067,620 | +28.1% | Q3 2026 |
| Bridgewater Associates | 476,249 | $33,256,468 | +254.9% | Q3 2026 |
| Millennium Management | 409,865 | $28,620,873 | -77.4% | Q3 2026 |
| Wellington Management | 172,349 | $12,035,131 | -98.2% | Q3 2026 |
| Two Sigma Investments | 168,491 | $11,765,727 | -56.4% | Q3 2026 |
| Soros Fund Management | 27,808 | $1,998,283 | — | Q2 2026 |
| T. Rowe Price | 799,492 | $55,829 | -29.8% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.